{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Deb G"],"funding":["Cancer Research UK"],"pagination":["1266-1277"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7192845"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["34(5)"],"pubmed_abstract":["The histone demethylase lysine-specific demethylase 1 (LSD1 or KDM1A) has emerged as a candidate therapeutic target in acute myeloid leukaemia (AML); tranylcypromine-derivative inhibitors induce loss of clonogenic activity and promote differentiation, in particular in the MLL-translocated molecular subtype of AML. In AML, the use of drugs in combination often delivers superior clinical activity. To identify genes and cellular pathways that collaborate with LSD1 to maintain the leukaemic phenotype, and which could be targeted by combination therapies, we performed a genome-wide CRISPR-Cas9 dropout screen. We identified multiple components of the amino acid sensing arm of mTORC1 signalling-RRAGA, MLST8, WDR24 and LAMTOR2-as cellular sensitizers to LSD1 inhibition. Knockdown of mTORC1 compone"],"journal":["Leukemia"],"pubmed_title":["Pre-clinical activity of combined LSD1 and mTORC1 inhibition in MLL-translocated acute myeloid leukaemia."],"pmcid":["PMC7192845"],"funding_grant_id":["C147/A25254","S_3492","A18083","29389","C5759/A20971","19280"],"pubmed_authors":["Somervaille TCP","Deb G","Williams EL","Leong HS","Amaral FMR","Maiques-Diaz A","Maes T","Spencer GJ","Wingelhofer B","Chadwick JA"],"additional_accession":[]},"is_claimable":false,"name":"Pre-clinical activity of combined LSD1 and mTORC1 inhibition in MLL-translocated acute myeloid leukaemia.","description":"The histone demethylase lysine-specific demethylase 1 (LSD1 or KDM1A) has emerged as a candidate therapeutic target in acute myeloid leukaemia (AML); tranylcypromine-derivative inhibitors induce loss of clonogenic activity and promote differentiation, in particular in the MLL-translocated molecular subtype of AML. In AML, the use of drugs in combination often delivers superior clinical activity. To identify genes and cellular pathways that collaborate with LSD1 to maintain the leukaemic phenotype, and which could be targeted by combination therapies, we performed a genome-wide CRISPR-Cas9 dropout screen. We identified multiple components of the amino acid sensing arm of mTORC1 signalling-RRAGA, MLST8, WDR24 and LAMTOR2-as cellular sensitizers to LSD1 inhibition. Knockdown of mTORC1 compone","dates":{"release":"2020-01-01T00:00:00Z","publication":"2020 May","modification":"2026-05-02T17:35:09.811Z","creation":"2020-05-22T19:56:59Z"},"accession":"S-EPMC7192845","cross_references":{"pubmed":["31780813"],"doi":["10.1038/s41375-019-0659-6"]}}